Study identifier:D5127L00001
ClinicalTrials.gov identifier:NCT01749462
EudraCT identifier:N/A
CTIS identifier:N/A
Oxis 9mcg Turbuhaler Clinical Experience Investigation
Chronic Obstructive Pulmonary Disease
-
No
-
All
398
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Feb 2017 by AstraZeneca
AstraZeneca
-
The purpose of the investigation is to confirm the ADR development and the contributing factors possibly having an impact on the safety under the post-marketing actual use of Oxis 9 mcg Turbuhaler.
Oxis 9mcg Turbuhaler Clinical Experience Investigation
Location
Location
Hokkaido, D5127L00001, Japan
Location
Miyagi, D5127L00001, Japan
Location
Aomori, D5127L00001, Japan
Location
Iwate, D5127L00001, Japan
Location
Akita, D5127L00001, Japan
Location
Yamagata, D5127L00001, Japan
Location
Fukushima, D5127L00001, Japan
Location
Tokyo, D5127L00001, Japan
Arms | Assigned Interventions |
---|---|
Oxis | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.